According to NICE guidelines, women who are due for routine cervical screening should wait until 12 weeks after giving birth. If a woman has had an abnormal smear in the past and becomes pregnant, she should seek specialist advice. If there are no contraindications, such as a low-lying placenta, a cervical smear can be performed during the middle trimester of pregnancy. It is crucial to encourage women to participate in regular cervical screening.

Cervical Cancer Screening in the UK

Cervical cancer screening is a well-established program in the UK that aims to detect pre-malignant changes in the cervix. This program is estimated to prevent 1,000-4,000 deaths per year. However, it should be noted that around 15% of cervical adenocarcinomas are frequently undetected by screening.

The screening program has evolved significantly in recent years. Initially, smears were examined for signs of dyskaryosis, which may indicate cervical intraepithelial neoplasia. However, the introduction of HPV testing allowed for further risk stratification, and the NHS has now moved to an HPV first system. This means that a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

All women between the ages of 25-64 years are offered a smear test. Women aged 25-49 years are screened every three years, while those aged 50-64 years are screened every five years. However, cervical screening cannot be offered to women over 64. In Scotland, screening is offered from 25-64 every five years.

In special situations, cervical screening in pregnancy is usually delayed until three months post-partum, unless there are missed screenings or previous abnormal smears. Women who have never been sexually active have a very low risk of developing cervical cancer and may wish to opt-out of screening.

It is recommended to take a cervical smear around mid-cycle, although there is limited evidence to support this advice. Overall, the UK’s cervical cancer screening program is an essential tool in preventing cervical cancer and promoting women’s health.

Factor V Leiden is a genetic condition that causes resistance to the breakdown of Factor V by activated Protein C, leading to an increased risk of blood clots. The RCOG has issued guidelines (Green-top Guideline No.37a) for preventing blood clots in pregnant women with this condition. As this patient has a history of VTE, she is at high risk during and after pregnancy and requires both antenatal and postnatal thromboprophylaxis. It is important to note that postnatal prophylaxis must be given for six weeks following antenatal prophylaxis.

Venous Thromboembolism in Pregnancy: Risk Assessment and Prophylactic Measures

Pregnancy increases the risk of developing venous thromboembolism (VTE), a condition that can be life-threatening for both the mother and the fetus. To prevent VTE, it is important to assess a woman’s individual risk during pregnancy and initiate appropriate prophylactic measures. This risk assessment should be done at the first antenatal booking and on any subsequent hospital admission.

Women with a previous history of VTE are automatically considered high risk and require low molecular weight heparin throughout the antenatal period, as well as input from experts. Women at intermediate risk due to hospitalization, surgery, co-morbidities, or thrombophilia should also be considered for antenatal prophylactic low molecular weight heparin.

The risk assessment at booking should include factors that increase the likelihood of developing VTE, such as age over 35, body mass index over 30, parity over 3, smoking, gross varicose veins, current pre-eclampsia, immobility, family history of unprovoked VTE, low-risk thrombophilia, multiple pregnancy, and IVF pregnancy.

If a woman has four or more risk factors, immediate treatment with low molecular weight heparin should be initiated and continued until six weeks postnatal. If a woman has three risk factors, low molecular weight heparin should be initiated from 28 weeks and continued until six weeks postnatal.

If a diagnosis of deep vein thrombosis (DVT) is made shortly before delivery, anticoagulation treatment should be continued for at least three months, as in other patients with provoked DVTs. Low molecular weight heparin is the treatment of choice for VTE prophylaxis in pregnancy, while direct oral anticoagulants (DOACs) and warfarin should be avoided.

In summary, a thorough risk assessment and appropriate prophylactic measures can help prevent VTE in pregnancy, which is crucial for the health and safety of both the mother and the fetus.

All pregnant women who develop hypertension (systolic blood pressure over 140 mmHg or diastolic blood pressure over 90 mmHg) after 20 weeks of pregnancy should receive a secondary care assessment by a healthcare professional trained in managing hypertensive disorders of pregnancy. It is not recommended to delay this assessment by monitoring blood pressure over several days or providing lifestyle advice alone. The obstetric department may initiate antihypertensive medication and aspirin for the patient, but those with a blood pressure of 160/110 or higher are likely to be admitted for further monitoring and treatment.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, and age over 40. Aspirin may be recommended for women with high or moderate risk factors. Treatment involves emergency assessment, admission for observation, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

If blood glucose targets are not achieved through diet and metformin in gestational diabetes, insulin should be added to the treatment plan. This patient was initially advised to make lifestyle changes and follow a specific diet for two weeks, as her fasting blood glucose was below 7 mmol/L. However, since she did not meet the targets, she was started on metformin monotherapy. Insulin therapy was not initiated earlier because her fasting blood glucose was below 7 mmol/L. According to NICE guidelines, if metformin monotherapy fails to achieve the desired results, insulin should be started, and lifestyle changes should be emphasized. Therefore, the correct answer is to continue metformin and add insulin to the patient’s treatment plan. The other options, such as increasing the dose of metformin, stopping metformin and starting insulin, adding gliclazide, or prescribing high-dose folic acid, are incorrect.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

The symptoms described in this question are indicative of a molar pregnancy. To answer this question correctly, a basic understanding of physiology is necessary. Molar pregnancies are characterized by abnormally high levels of beta hCG for the stage of pregnancy, which serves as a tumor marker for gestational trophoblastic disease. Beta hCG has a similar biochemical structure to luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH). Consequently, elevated levels of beta hCG can stimulate the thyroid gland to produce thyroxine (T4) and triiodothyronine (T3), leading to symptoms of thyrotoxicosis. High levels of T4 and T3 negatively impact the pituitary gland, reducing TSH levels overall.
Sources:
Best Practice- Molar Pregnancy
Medscape- Hydatidiform Mole Workup

Gestational trophoblastic disorders refer to a range of conditions that originate from the placental trophoblast. These disorders include complete hydatidiform mole, partial hydatidiform mole, and choriocarcinoma. Complete hydatidiform mole is a benign tumor of trophoblastic material that occurs when an empty egg is fertilized by a single sperm that duplicates its own DNA, resulting in all 46 chromosomes being of paternal origin. Symptoms of this disorder include bleeding in the first or early second trimester, exaggerated pregnancy symptoms, a uterus that is large for dates, and very high levels of human chorionic gonadotropin (hCG) in the serum. Hypertension and hyperthyroidism may also be present. Urgent referral to a specialist center is necessary, and evacuation of the uterus is performed. Effective contraception is recommended to avoid pregnancy in the next 12 months, as around 2-3% of cases may develop choriocarcinoma.

Partial hydatidiform mole, on the other hand, occurs when a normal haploid egg is fertilized by two sperms or by one sperm with duplication of the paternal chromosomes. As a result, the DNA is both maternal and paternal in origin, and the fetus may have triploid chromosomes, such as 69 XXX or 69 XXY. Fetal parts may also be visible. It is important to note that hCG can mimic thyroid-stimulating hormone (TSH), which may lead to hyperthyroidism.

In summary, gestational trophoblastic disorders are a group of conditions that arise from the placental trophoblast. Complete hydatidiform mole and partial hydatidiform mole are two types of these disorders. While complete hydatidiform mole is a benign tumor of trophoblastic material that occurs when an empty egg is fertilized by a single sperm that duplicates its own DNA, partial hydatidiform mole occurs when a normal haploid egg is fertilized by two sperms or by one sperm with duplication of the paternal chromosomes. It is important to seek urgent medical attention and effective contraception to avoid pregnancy in the next 12 months.

While many symptoms experienced during pregnancy are normal and not a cause for concern, it is important to be aware of symptoms that may indicate a medical issue, such as dysuria.

Dysuria, or painful urination, can be a sign of a urinary tract infection (UTI), which should be treated promptly during any stage of pregnancy. UTIs have been linked to premature birth, as the inflammation caused by the infection can irritate the cervix and trigger preterm labor.

Fatigue during pregnancy is a common experience and can have multiple causes. In the third trimester, it is considered normal. Lower back pain is also a common symptom, caused by the hormone relaxin increasing laxity in the sacroiliac joints and the added mechanical strain of pregnancy.

Nausea and vomiting are most commonly experienced in the first trimester, but can still occur throughout pregnancy and are generally considered normal.

Minor Symptoms of Pregnancy

During pregnancy, women may experience minor symptoms that are common and not usually a cause for concern. These symptoms may include nausea and vomiting, tiredness, and musculoskeletal pains. Nausea and vomiting, commonly known as morning sickness, can occur at any time of the day and may last throughout the first trimester. Tiredness is also a common symptom, especially during the first and third trimesters. Musculoskeletal pains, such as back pain and pelvic pain, may also occur due to the changes in the body’s structure and weight distribution. While these symptoms may be uncomfortable, they are typically manageable and can be relieved with rest, exercise, and proper nutrition. It is important to consult with a healthcare provider if these symptoms become severe or persistent.

Pre-eclampsia Risk Factors in Pregnancy

During the first prenatal visit, women are screened for their risk of developing pre-eclampsia during pregnancy.

High-risk factors include a personal history of pre-eclampsia, essential hypertension, type 1 or 2 diabetes mellitus, chronic kidney disease, or autoimmune conditions.

Moderate risk factors include a BMI of 35-39.9 kg/m2, family history of pre-eclampsia, age of ≥ 40, first pregnancy, multiple pregnancy, and an interpregnancy interval of > 10 years. If any high or moderate risk factor is present, it is recommended that the woman take 75 mg of aspirin daily from the 12th week of gestation until delivery.

A personal history of DVT is not a risk factor for pre-eclampsia, but it is associated with an increased risk of thrombi during pregnancy and the puerperium.

Referral to gynaecology for urgent assessment and intravenous fluids is necessary if a pregnant woman experiences severe nausea and vomiting, weight loss, and positive ketones in her urine. This is especially important if the woman has a pre-existing condition that may be affected by prolonged nausea and vomiting, such as diabetes. Caution should be exercised when prescribing metoclopramide to young women due to the risk of extrapyramidal side effects. In this case, hospital management and assessment for intravenous fluids are necessary, and it would not be appropriate to simply reassure the patient and discharge her.

Hyperemesis gravidarum is an extreme form of nausea and vomiting of pregnancy that occurs in around 1% of pregnancies and is most common between 8 and 12 weeks. It is associated with raised beta hCG levels and can be caused by multiple pregnancies, trophoblastic disease, hyperthyroidism, nulliparity, and obesity. Referral criteria for nausea and vomiting in pregnancy include continued symptoms with ketonuria and/or weight loss, a confirmed or suspected comorbidity, and inability to keep down liquids or oral antiemetics. The diagnosis of hyperemesis gravidarum requires the presence of 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance. Management includes first-line use of antihistamines and oral cyclizine or promethazine, with second-line options of ondansetron and metoclopramide. Admission may be needed for IV hydration. Complications can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth issues.

The use of ondansetron during pregnancy has been associated with an increased risk of 3 oral clefts per 10,000 births, according to a study. However, this risk is not included in the RCOG guideline on nausea and vomiting of pregnancy, and there is currently no official NICE guidance on the matter. A draft of NICE antenatal care guidance, published in August 2021, acknowledges the increased risk of cleft lip or palate with ondansetron use, but notes that there is conflicting evidence regarding the drug’s potential to cause heart problems in babies. It is important to note that the risk of spontaneous miscarriage in twin pregnancies is not supported by evidence, and there is no established risk of severe congenital heart defects in newborns associated with ondansetron use.

Hyperemesis gravidarum is an extreme form of nausea and vomiting of pregnancy that occurs in around 1% of pregnancies and is most common between 8 and 12 weeks. It is associated with raised beta hCG levels and can be caused by multiple pregnancies, trophoblastic disease, hyperthyroidism, nulliparity, and obesity. Referral criteria for nausea and vomiting in pregnancy include continued symptoms with ketonuria and/or weight loss, a confirmed or suspected comorbidity, and inability to keep down liquids or oral antiemetics. The diagnosis of hyperemesis gravidarum requires the presence of 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance. Management includes first-line use of antihistamines and oral cyclizine or promethazine, with second-line options of ondansetron and metoclopramide. Admission may be needed for IV hydration. Complications can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth issues.

The recommended treatment for gestational diabetes is short-acting insulin, not longer-acting subcutaneous insulin. If lifestyle modifications and metformin do not improve the condition, the next step is to provide education on how to dose insulin in accordance with meals and offer short-acting insulin. Glibenclamide and gliclazide are not recommended for use in pregnancy due to the risk of adverse birth outcomes and neonatal hypoglycemia. Prescribing both drugs together or long-acting insulin is also not recommended. Short-acting insulin alone provides better postprandial glucose control and is more flexible in responding to the varying diets of pregnant women.

Gestational diabetes is a common medical disorder affecting around 4% of pregnancies. Risk factors include a high BMI, previous gestational diabetes, and family history of diabetes. Screening is done through an oral glucose tolerance test, and diagnostic thresholds have recently been updated. Management includes self-monitoring of blood glucose, diet and exercise advice, and medication if necessary. For pre-existing diabetes, weight loss and insulin are recommended, and tight glycemic control is important. Targets for self-monitoring include fasting glucose of 5.3 mmol/l and 1-2 hour post-meal glucose levels.

The most probable condition is cholestasis of pregnancy, which is indicated by intense itching, jaundice, obstructive liver function tests, normal white blood cell count, and absence of coagulopathy. Severe itching is a typical symptom of cholestasis of pregnancy, while acute fatty liver of pregnancy presents with non-specific symptoms such as fatigue, malaise, and nausea. Given the normal results of the full blood count and viral screening, it is unlikely that the patient has HELLP syndrome or viral hepatitis. Lastly, pre-eclampsia is characterized by high blood pressure and protein in the urine.

Liver Complications During Pregnancy

During pregnancy, there are several liver complications that may arise. One of the most common is intrahepatic cholestasis of pregnancy, which occurs in about 1% of pregnancies and is typically seen in the third trimester. Symptoms include intense itching, especially in the palms and soles, as well as elevated bilirubin levels. Treatment involves the use of ursodeoxycholic acid for relief and weekly liver function tests. Women with this condition are usually induced at 37 weeks to prevent stillbirth, although maternal morbidity is not typically increased.

Another rare complication is acute fatty liver of pregnancy, which may occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea and vomiting, headache, jaundice, and hypoglycemia. Severe cases may result in pre-eclampsia. ALT levels are typically elevated, and support care is the primary management until delivery can be performed once the patient is stabilized.

Finally, conditions such as Gilbert’s and Dubin-Johnson syndrome may be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for haemolysis, elevated liver enzymes, and low platelets, is a serious complication that can occur in the third trimester and requires immediate medical attention. Overall, it is important for pregnant women to be aware of these potential liver complications and to seek medical attention if any symptoms arise.

Management of Tongue Tie in Infants: Referral for Frenotomy under No Anaesthesia

Tongue tie is a congenital condition that affects a baby’s ability to move their tongue due to a thickened frenulum. This can cause problems with breastfeeding and bottle feeding, leading to poor weight gain and irritability. In severe cases, a referral for frenotomy is necessary. In infants under three months of age, the procedure can be performed without anaesthesia, though local anaesthesia may be used. Conservative management and support with breastfeeding should be attempted first, but if unsuccessful, a frenotomy should be performed as early as possible to give the baby and mother the best chance at successful feeding. Frenotomy under general anaesthesia is only necessary for infants over three months of age. Converting to bottle feeding is not a solution in severe cases of tongue tie.

Understanding the Signs of a Good Latch for Successful Breastfeeding

Latching on the breast is crucial for successful breastfeeding, but many women struggle with it. A poor latch can lead to pain and frustration, causing some women to give up on breastfeeding altogether. However, there are clear signs of a good latch that can help mothers and babies achieve successful breastfeeding.

One indicator of a poor latch is clicking noises, which can be painful for the mother and indicate that the baby is chewing on the nipple. In contrast, a good latch is associated with visible and audible swallowing, a rhythmic suck, and relaxed arms and hands of the infant. The baby’s chin should touch the breast, with the nose free, and the lips should be rolled out, not turned in. The mouth should be open wide, and the tongue positioned below the nipple, with the latter touching the palate of the baby’s mouth.

Another sign of a good latch is that less areola should be visible below the chin than above the nipple. This indicates that the baby is taking in not only the nipple but also the areola, which is essential for effective milk expression and feeding. By understanding these signs of a good latch, mothers can ensure successful breastfeeding and a positive experience for both themselves and their babies.

When babies are born to mothers who are hepatitis B surface antigen positive or are at high risk of developing hepatitis B, they should receive the first dose of the hepatitis B vaccine shortly after birth. Additionally, babies born to surface antigen positive mothers should receive 0.5 millilitres of hepatitis B immunoglobulin within 12 hours of birth. The second and third doses of the hepatitis B vaccine should be given at 1-2 months and 6 months, respectively.

Hepatitis B and Pregnancy: Screening and Prevention

During pregnancy, all women are offered screening for hepatitis B. If a mother is found to be chronically infected with hepatitis B or has had acute hepatitis B during pregnancy, it is important that her baby receives a complete course of vaccination and hepatitis B immunoglobulin. Currently, studies are being conducted to evaluate the effectiveness of oral antiviral treatment, such as Lamivudine, in the latter part of pregnancy.

There is little evidence to suggest that a caesarean section reduces the risk of vertical transmission of hepatitis B. However, it is important to note that hepatitis B cannot be transmitted through breastfeeding, unlike HIV. It is crucial for pregnant women to undergo screening for hepatitis B to ensure the health and safety of both the mother and the baby. With proper prevention and treatment, the risk of transmission can be greatly reduced.

Antepartum Haemorrhage: Causes and Differential Diagnosis

Antepartum haemorrhage can be caused by various conditions, including placenta praevia, placental abruption, genitourinary infection, and premature labour. Placenta praevia occurs when the placenta covers the internal cervical os, leading to painless vaginal bleeding. Risk factors include maternal age, multiparity, and smoking. Diagnosis is made through ultrasound scanning, and close monitoring is necessary to prevent rebleeding. Placental abruption can be revealed or concealed, with the former causing significant abdominal pain and vaginal bleeding, while the latter is confined within the uterus. Genitourinary infection should also be considered, although this patient’s urinalysis is unremarkable. Premature labour, which is associated with cyclical abdominal pain, is another possible cause of antepartum bleeding. However, this patient presents without pain. A thorough differential diagnosis is crucial in managing antepartum haemorrhage.

At 32 weeks gestation, this woman may be experiencing labor with ruptured membranes. It is important to admit her and administer steroids to promote the baby’s lung development. Antibiotics, such as erythromycin, should also be given to prevent sepsis and post-natal infection. Hospital guidelines should always be consulted, especially if Group B streptococcus is present, in which case penicillin and clindamycin may be used. If labor does not progress, the woman may be able to manage at home with temperature checks every 4-8 hours and returning to the hospital if a fever occurs. Delivery at 34 weeks may be considered if the risk of infection outweighs the risk of prematurity now that the baby’s lungs have matured.

Preterm prelabour rupture of the membranes (PPROM) is a condition that occurs in approximately 2% of pregnancies, but it is responsible for around 40% of preterm deliveries. This condition can lead to various complications, including prematurity, infection, and pulmonary hypoplasia in the fetus, as well as chorioamnionitis in the mother. To confirm PPROM, a sterile speculum examination should be performed to check for pooling of amniotic fluid in the posterior vaginal vault. However, digital examination should be avoided due to the risk of infection. If pooling of fluid is not observed, testing the fluid for placental alpha microglobulin-1 protein (PAMG-1) or insulin-like growth factor binding protein-1 is recommended. Ultrasound may also be useful to show oligohydramnios.

The management of PPROM involves admission and regular observations to ensure that chorioamnionitis is not developing. Oral erythromycin should be given for ten days, and antenatal corticosteroids should be administered to reduce the risk of respiratory distress syndrome. Delivery should be considered at 34 weeks of gestation, but there is a trade-off between an increased risk of maternal chorioamnionitis and a decreased risk of respiratory distress syndrome as the pregnancy progresses. PPROM is a serious condition that requires prompt diagnosis and management to minimize the risk of complications for both the mother and the fetus.

When a pregnant woman is exposed to chickenpox, it can lead to serious complications for both her and the developing fetus. To prevent this, the first step is to check the woman’s immune status by testing for varicella antibodies. If she is found to be non-immune, she should be given varicella-zoster immune globulin (VZIG) as soon as possible for post-exposure prophylaxis (PEP). This can be arranged by the GP, although the midwife should also be informed.

If the woman is less than 20 weeks pregnant and non-immune, VZIG should be given within 10 days of exposure. If she is more than 20 weeks pregnant and develops chickenpox, oral acyclovir or an equivalent antiviral should be started within 24 hours of rash onset. If the woman is less than 20 weeks pregnant, specialist advice should be sought.

It is important to take action if the woman is found to be non-immune, as providing only reassurance is not appropriate in this situation. By administering VZIG or antivirals, the risk of complications for both the woman and the fetus can be greatly reduced.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral acyclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

To ensure that a pregnant woman has not been exposed to chickenpox before, the initial step is to test her blood for varicella antibodies.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral acyclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

The symptoms of HELLP syndrome, a severe form of pre-eclampsia, include haemolysis (H), elevated liver enzymes (EL), and low platelets (LP). A patient with this condition may experience malaise, nausea, vomiting, and headache, as well as hypertension with proteinuria and epigastric and/or upper abdominal pain. The patient in this case meets the requirements for a diagnosis of HELLP syndrome.

Liver Complications During Pregnancy

During pregnancy, there are several liver complications that may arise. One of the most common is intrahepatic cholestasis of pregnancy, which occurs in about 1% of pregnancies and is typically seen in the third trimester. Symptoms include intense itching, especially in the palms and soles, as well as elevated bilirubin levels. Treatment involves the use of ursodeoxycholic acid for relief and weekly liver function tests. Women with this condition are usually induced at 37 weeks to prevent stillbirth, although maternal morbidity is not typically increased.

Another rare complication is acute fatty liver of pregnancy, which may occur in the third trimester or immediately after delivery. Symptoms include abdominal pain, nausea and vomiting, headache, jaundice, and hypoglycemia. Severe cases may result in pre-eclampsia. ALT levels are typically elevated, and support care is the primary management until delivery can be performed once the patient is stabilized.

Finally, conditions such as Gilbert’s and Dubin-Johnson syndrome may be exacerbated during pregnancy. Additionally, HELLP syndrome, which stands for haemolysis, elevated liver enzymes, and low platelets, is a serious complication that can occur in the third trimester and requires immediate medical attention. Overall, it is important for pregnant women to be aware of these potential liver complications and to seek medical attention if any symptoms arise.

In the case of umbilical cord prolapse, the priority is to limit compression on the cord and reduce the chance of cord vasospasm. This can be achieved by pushing any presenting part of the baby back into the uterus, putting the mother on all fours, and retrofilling the bladder with saline. In addition, warm damp towels can be placed over the cord to limit handling. It is important to note that this is a complex emergency that requires immediate attention, as it can lead to foetal bradycardia and limit the oxygen supply to the baby. In this scenario, a category 1 Caesarean section would be necessary, as the pathological CTG demands it. Delivering the baby as breech immediately is not recommended, as it is a high-risk strategy that can lead to morbidity and mortality. IM corticosteroids are indicated for premature rupture of membranes, but the immediate priority is to deal with the emergency. McRobert’s manoeuvre is not appropriate in this case, as it is used to correct shoulder dystocia, which is not the issue at hand.

Understanding Umbilical Cord Prolapse

Umbilical cord prolapse is a rare but serious complication that can occur during delivery. It happens when the umbilical cord descends ahead of the presenting part of the fetus, which can lead to compression or spasm of the cord. This can cause fetal hypoxia and potentially irreversible damage or death. Certain factors increase the risk of cord prolapse, such as prematurity, multiparity, polyhydramnios, twin pregnancy, cephalopelvic disproportion, and abnormal presentations like breech or transverse lie.

Around half of all cord prolapses occur when the membranes are artificially ruptured. Diagnosis is usually made when the fetal heart rate becomes abnormal and the cord is palpable vaginally or visible beyond the introitus. Cord prolapse is an obstetric emergency that requires immediate management. The presenting part of the fetus may be pushed back into the uterus to avoid compression, and the cord should be kept warm and moist to prevent vasospasm. The patient may be asked to go on all fours or assume the left lateral position until preparations for an immediate caesarian section have been carried out. Tocolytics may be used to reduce uterine contractions, and retrofilling the bladder with saline can help elevate the presenting part. Although caesarian section is the usual first-line method of delivery, an instrumental vaginal delivery may be possible if the cervix is fully dilated and the head is low.

In conclusion, umbilical cord prolapse is a rare but serious complication that requires prompt recognition and management. Understanding the risk factors and appropriate interventions can help reduce the incidence of fetal mortality associated with this condition.

Mothers often have concerns about the use of antiepileptic medication during and after pregnancy, particularly when it comes to breastfeeding. However, according to a comprehensive document released by the Royal College of Obstetricians and Gynaecologists, nearly all antiepileptic drugs are safe to use while breastfeeding. This is because only negligible amounts of the medication are passed to the baby through breast milk, and studies have not shown any negative impact on the child’s cognitive development. Therefore, it is recommended that mothers continue their current antiepileptic regime and are encouraged to breastfeed. It is important to note that stopping the medication without consulting a neurologist can lead to further seizures.

Pregnancy and breastfeeding can be a concern for women with epilepsy. It is generally recommended that women continue taking their medication during pregnancy, as the risks of uncontrolled seizures outweigh the potential risks to the fetus. However, it is important for women to take folic acid before pregnancy to reduce the risk of neural tube defects. The use of antiepileptic medication during pregnancy can increase the risk of congenital defects, but this risk is still relatively low. It is recommended to aim for monotherapy and there is no need to monitor drug levels. Sodium valproate is associated with neural tube defects, while carbamazepine is considered the least teratogenic of the older antiepileptics. Phenytoin is associated with cleft palate, and lamotrigine may require a dose increase during pregnancy. Breastfeeding is generally safe for mothers taking antiepileptics, except for barbiturates. Pregnant women taking phenytoin should be given vitamin K in the last month of pregnancy to prevent clotting disorders in the newborn.

A warning has been issued about the use of sodium valproate during pregnancy and in women of childbearing age. New evidence suggests a significant risk of neurodevelopmental delay in children following maternal use of this medication. Therefore, it should only be used if clearly necessary and under specialist neurological or psychiatric advice. It is important for women with epilepsy to discuss their options with their healthcare provider and make informed decisions about their treatment during pregnancy and breastfeeding.

NICE guidelines recommend 10 antenatal visits for first pregnancies and 7 for subsequent pregnancies if uncomplicated. The purpose of each visit is outlined, including booking visits, scans, screening for Down’s syndrome, routine care for blood pressure and urine, and discussions about labour and birth plans. Rhesus negative women are offered anti-D prophylaxis at 28 and 34 weeks. The guidelines also recommend discussing options for prolonged pregnancy at 41 weeks.

A woman at 12 weeks gestation is seeking Down syndrome screening. Although her age increases the likelihood of her fetus having Down’s syndrome, it will not affect the initial screening process. The standard screening method involves an ultrasound to evaluate nuchal translucency and serum testing to measure levels of β-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein A (PAPP-A). This combined screening can also detect Edward’s (trisomy 18) and Patau (trisomy 13) syndromes. The triple test, which includes α-fetoprotein, unconjugated oestriol, and β-hCG, is conducted between 15-20 weeks gestation to assess for Down’s syndrome. The quadruple test is also an option for women who have missed the window for combined antenatal screening. A biophysical profile, which evaluates fetal wellbeing through ultrasound detection of heart rate, breathing, movement, tone, and amniotic fluid volume, is used to determine the need for rapid induction of labor.

NICE updated guidelines on antenatal care in 2021, recommending the combined test for screening for Down’s syndrome between 11-13+6 weeks. The test includes nuchal translucency measurement, serum B-HCG, and pregnancy-associated plasma protein A (PAPP-A). The quadruple test is offered between 15-20 weeks for women who book later in pregnancy. Results are interpreted as either a ‘lower chance’ or ‘higher chance’ of chromosomal abnormalities. If a woman receives a ‘higher chance’ result, she may be offered a non-invasive prenatal screening test (NIPT) or a diagnostic test. NIPT analyzes cell-free fetal DNA in the mother’s blood and has high sensitivity and specificity for detecting chromosomal abnormalities. Private companies offer NIPT screening from 10 weeks gestation.

Eclampsia: Symptoms and Treatment

Eclampsia is a serious medical condition that can occur during pregnancy, characterized by pre-eclampsia and seizure activity. Symptoms may include hypertension, proteinuria, mental status changes, and blurred vision. Immediate delivery is the only definitive treatment for eclampsia, but magnesium can be given to reduce the risk of seizures in women with severe pre-eclampsia who are delivering within 24 hours. Eclampsia is more common in younger women with their first pregnancy and those with underlying vascular disorders. Hydralazine can be used to manage hypertension in pregnant women, but it is not the definitive treatment for eclampsia. Conservative management, such as salt and water restriction, bed rest, and close monitoring of blood pressure, is not appropriate for patients with eclampsia and associated seizure and mental state changes. ACE inhibitors are contraindicated during pregnancy, and labetalol is the first-line antihypertensive in pregnancy. Diazepam and magnesium sulfate can reduce seizures in eclampsia, but they are not the definitive treatment.

According to RCOG guidelines, women typically feel fetal movements by 20 weeks of gestation. However, if no movements are felt by 24 weeks, it is recommended to refer the woman to a maternal fetal medicine unit to assess for potential neuromuscular conditions.

Understanding Reduced Fetal Movements

Introduction:
Reduced fetal movements can indicate fetal distress and are a response to chronic hypoxia in utero. This can lead to stillbirth and fetal growth restriction. It is believed that placental insufficiency may also be linked to reduced fetal movements.

Physiology:
Quickening is the first onset of fetal movements, which usually occurs between 18-20 weeks gestation and increases until 32 weeks gestation. Multiparous women may experience fetal movements sooner. Fetal movements should not reduce towards the end of pregnancy. There is no established definition for what constitutes reduced fetal movements, but less than 10 movements within 2 hours (in pregnancies past 28 weeks gestation) is an indication for further assessment.

Epidemiology:
Reduced fetal movements affect up to 15% of pregnancies, with 3-5% of pregnant women having recurrent presentations with RFM. Fetal movements should be established by 24 weeks gestation.

Risk factors for reduced fetal movements:
Posture, distraction, placental position, medication, fetal position, body habitus, amniotic fluid volume, and fetal size can all affect fetal movement awareness.

Investigations:
Fetal movements are usually based on maternal perception, but can also be objectively assessed using handheld Doppler or ultrasonography. Investigations are dependent on gestation at onset of RFM. If concern remains, despite normal CTG, urgent (within 24 hours) ultrasound can be used.

Prognosis:
Reduced fetal movements can represent fetal distress, but in 70% of pregnancies with a single episode of reduced fetal movement, there is no onward complication. However, between 40-55% of women who suffer from stillbirth experience reduced fetal movements prior to diagnosis. Recurrent RFM requires further investigations to consider structural or genetic fetal abnormalities.

All women with PPROM should receive a 10-day course of erythromycin. This is the recommended treatment for this condition. Piperacillin and tazobactam (tazocin) is not appropriate due to the patient’s penicillin allergy. Nitrofurantoin is used for urinary tract infections, while vancomycin is typically used for anaerobic GI infections.

Preterm prelabour rupture of the membranes (PPROM) is a condition that occurs in approximately 2% of pregnancies, but it is responsible for around 40% of preterm deliveries. This condition can lead to various complications, including prematurity, infection, and pulmonary hypoplasia in the fetus, as well as chorioamnionitis in the mother. To confirm PPROM, a sterile speculum examination should be performed to check for pooling of amniotic fluid in the posterior vaginal vault. However, digital examination should be avoided due to the risk of infection. If pooling of fluid is not observed, testing the fluid for placental alpha microglobulin-1 protein (PAMG-1) or insulin-like growth factor binding protein-1 is recommended. Ultrasound may also be useful to show oligohydramnios.

The management of PPROM involves admission and regular observations to ensure that chorioamnionitis is not developing. Oral erythromycin should be given for ten days, and antenatal corticosteroids should be administered to reduce the risk of respiratory distress syndrome. Delivery should be considered at 34 weeks of gestation, but there is a trade-off between an increased risk of maternal chorioamnionitis and a decreased risk of respiratory distress syndrome as the pregnancy progresses. PPROM is a serious condition that requires prompt diagnosis and management to minimize the risk of complications for both the mother and the fetus.

The symptoms described in the question suggest that the patient is experiencing placental abruption, which can be caused by cocaine abuse, pre-eclampsia, and HELLP syndrome. The presence of hyperreflexia on physical examination indicates placental abruption, while ruling out HELLP syndrome due to normal blood count results. Dilated pupils and hyperreflexia are consistent with cocaine abuse, while pinpointed pupils are more commonly associated with heroin abuse. Although pre-eclampsia can also lead to placental abruption, the physical exam findings suggest cocaine abuse as the underlying cause. Disseminated intravascular coagulopathy is a complication of placental abruption, not a cause, and the normal PTT and APTT results make it less likely to be present.

Risks of Smoking, Alcohol, and Illegal Drugs During Pregnancy

During pregnancy, drug use can have serious consequences for both the mother and the developing fetus. Smoking during pregnancy increases the risk of miscarriage, preterm labor, stillbirth, and sudden unexpected death in infancy. Alcohol consumption can lead to fetal alcohol syndrome, which can cause learning difficulties, characteristic facial features, and growth restrictions. Binge drinking is a major risk factor for fetal alcohol syndrome. Cannabis use poses similar risks to smoking due to the tobacco content. Cocaine use can lead to hypertension in pregnancy, including pre-eclampsia, and placental abruption. Fetal risks include prematurity and neonatal abstinence syndrome. Heroin use can result in neonatal abstinence syndrome. It is important for pregnant women to avoid drug use to ensure the health and well-being of both themselves and their unborn child.

To monitor her throughout her pregnancy and postnatal period, this woman requires a referral to a perinatal mental health team due to her increased risk of postpartum psychosis. It would have been preferable for her to receive preconception advice before becoming pregnant. The recurrence rate is not influenced by the baby’s gender.

Understanding Postpartum Mental Health Problems

Postpartum mental health problems can range from mild ‘baby-blues’ to severe puerperal psychosis. To screen for depression, healthcare professionals may use the Edinburgh Postnatal Depression Scale, which is a 10-item questionnaire that indicates how the mother has felt over the previous week. A score of more than 13 indicates a ‘depressive illness of varying severity’, with sensitivity and specificity of more than 90%. The questionnaire also includes a question about self-harm.

‘Baby-blues’ is seen in around 60-70% of women and typically occurs 3-7 days following birth. It is more common in primips, and mothers are characteristically anxious, tearful, and irritable. Reassurance and support from healthcare professionals, particularly health visitors, play a key role in managing this condition. Most women with the baby blues will not require specific treatment other than reassurance.

Postnatal depression affects around 10% of women, with most cases starting within a month and typically peaking at 3 months. The features are similar to depression seen in other circumstances, and cognitive behavioural therapy may be beneficial. Certain SSRIs such as sertraline and paroxetine may be used if symptoms are severe. Although these medications are secreted in breast milk, they are not thought to be harmful to the infant.

Puerperal psychosis affects approximately 0.2% of women and requires admission to hospital, ideally in a Mother & Baby Unit. Onset usually occurs within the first 2-3 weeks following birth, and features include severe swings in mood (similar to bipolar disorder) and disordered perception (e.g. auditory hallucinations). There is around a 25-50% risk of recurrence following future pregnancies. Paroxetine is recommended by SIGN because of the low milk/plasma ratio, while fluoxetine is best avoided due to a long half-life.

If a woman with stage IA cervical cancer wants to maintain her fertility, a cone biopsy with negative margins and close follow-up may be considered as the best option. Hysterectomy with or without lymph node clearance would not preserve fertility. Radical trachelectomy, which involves removing the cervix, upper part of the vagina, and surrounding tissues, and checking for cancer spread in the pelvis, is an option for IA2 tumors that also preserves fertility.

Management of Cervical Cancer Based on FIGO Staging

Cervical cancer management is determined by the FIGO staging and the patient’s desire to maintain fertility. The FIGO staging system categorizes cervical cancer into four stages based on the extent of the tumor’s spread. Stage IA and IB tumors are confined to the cervix, with IA tumors only visible under a microscope and less than 7 mm wide. Stage II tumors have spread beyond the cervix but not to the pelvic wall, while stage III tumors have spread to the pelvic wall. Stage IV tumors have spread beyond the pelvis or involve the bladder or rectum.

The management of stage IA tumors involves a hysterectomy with or without lymph node clearance. For patients who want to maintain fertility, a cone biopsy with negative margins can be performed, but close follow-up is necessary. Stage IB tumors are managed with radiotherapy and concurrent chemotherapy for B1 tumors and radical hysterectomy with pelvic lymph node dissection for B2 tumors.

Stage II and III tumors are managed with radiation and concurrent chemotherapy, with consideration for nephrostomy if hydronephrosis is present. Stage IV tumors are treated with radiation and/or chemotherapy, with palliative chemotherapy being the best option for stage IVB. Recurrent disease is managed with either surgical treatment followed by chemoradiation or radiotherapy followed by surgical therapy.

The prognosis of cervical cancer depends on the FIGO staging, with higher survival rates for earlier stages. Complications of treatments include standard surgical risks, increased risk of preterm birth with cone biopsies and radical trachelectomy, and ureteral fistula with radical hysterectomy. Complications of radiotherapy include short-term symptoms such as diarrhea and vaginal bleeding and long-term effects such as ovarian failure and fibrosis of various organs.

During the term of pregnancy, there is ample space for the fetus to reposition itself and move towards the head-down position. However, in cases of occipitoposterior presentation, the posterior fontanelle is located in the back quadrant of the pelvis, which requires more rotation and often results in a longer labor. Additionally, there is a higher likelihood of medical intervention, with a rate of 22.

Breech presentation occurs when the caudal end of the fetus is in the lower segment, and it is more common at 28 weeks than near term. Risk factors include uterine malformations, placenta praevia, and fetal abnormalities. Management options include spontaneous turning, external cephalic version (ECV), planned caesarean section, or vaginal delivery. The RCOG recommends informing women that planned caesarean section reduces perinatal mortality and early neonatal morbidity, but there is no evidence that the long-term health of babies is influenced by how they are born. ECV is contraindicated in certain cases, such as where caesarean delivery is required or there is an abnormal cardiotocography.